Core Viewpoint - The company, Zhaoyan New Drug (603127), has made a significant investment in financial products, which is expected to enhance its capital returns without affecting its financial stability or operational liquidity [1]. Group 1: Stock Performance - As of September 19, 2025, Zhaoyan New Drug's stock closed at 38.38 CNY, down 4.43% from the previous trading day [1]. - The stock opened at 39.5 CNY, reached a high of 40.55 CNY, and a low of 38.3 CNY, with a trading volume of 1.336 billion CNY and a turnover rate of 5.42% [1]. Group 2: Investment Announcement - The company announced that its subsidiary, Zhaoyan (Suzhou) New Drug, subscribed to two financial products from Industrial and Commercial Bank of China, totaling 40 million CNY [1]. - Including previously unredeemed products, the total investment amounts to 410 million CNY [1]. - The financial products are non-principal guaranteed, floating yield type, with no fixed term and flexible redemption arrangements [1]. Group 3: Regulatory Compliance - The investment constitutes a disclosure transaction as the combined applicable percentage rate is above 5% but below 25%, requiring compliance with notification and announcement regulations, but exempt from shareholder approval [1]. - The board believes that subscribing to these products will enhance capital returns and is in the overall interest of the company and its shareholders [1].

香港联交所最新资料显示，9月16日，富达国际减持昭衍新药（603127）(06127)161.08万股，每股均价 21.5742港元，总金额约为3475.17万港元。减持后最新持股数目为1145.48万股，最新持股比例为 9.63%。 本交易涉及其他关联方：Pandanus Associates Inc.、Pandanus Partners L.P.。 ...

本交易涉及其他关联方：Pandanus Associates Inc.、Pandanus Partners L.P.。 智通财经APP获悉，香港联交所最新资料显示，9月16日，富达国际减持昭衍新药(06127)161.08万股， 每股均价21.5742港元，总金额约为3475.17万港元。减持后最新持股数目为1145.48万股，最新持股比例 为9.63%。 ...

Company News - SF Holding (06936.HK) reported a total revenue of 24.787 billion yuan from its express logistics business in August, representing a year-on-year growth of 7.86% [2] - Guohao Group (00053.HK) announced its annual results for the year ending June 30, 2025, with revenue of 24.4 billion HKD, a year-on-year increase of 9%, and a net profit of 4.03 billion HKD, up 13% year-on-year [2] - Jieli Trading Treasure (08017.HK) launched the Deep Trade AI Agent, an intelligent trading system [2] - Innovent Biologics (01801.HK) received approval from the National Medical Products Administration for Masitinib to be used for blood sugar control in adult patients with type 2 diabetes [2] - Datang New Energy Group (00559.HK) issued a profit warning, expecting an annual net profit of 30 to 35 million HKD [2] - Zhonghuan New Energy (01735.HK) plans to collaborate with Ant Blockchain Technology (Shanghai) in the fields of new energy digital assets and new energy artificial intelligence ecosystem [2] - Fuhong Hanlin (02696.HK) received approval from the European Commission for the HLX14 product for the treatment of osteoporosis in specific populations [2] - Zhaoyan New Drug (06127.HK) subscribed to a financial product from Industrial and Commercial Bank of China worth 40 million yuan [2] Buyback Activities - Tencent Holdings (00700.HK) repurchased 857,000 shares at a cost of 551 million HKD, with repurchase prices ranging from 638.5 to 647 HKD [2] - HSBC Holdings (00005.HK) spent approximately 160 million HKD to buy back about 1.49 million shares, with repurchase prices between 106.9 and 107.6 HKD [3] - Shango Holdings (00412.HK) repurchased 3.7 million shares at a cost of approximately 22.623 million HKD, with repurchase prices ranging from 6.08 to 6.2 HKD [3]

Group 1 - The core point of the article is that Zhaoyan New Drug (06127.HK) has entered into an agreement with Industrial and Commercial Bank of China to subscribe to two wealth management products totaling RMB 40 million, bringing the total investment amount to RMB 410 million as of the announcement date [1] - As of September 19, 2025, Zhaoyan New Drug's stock closed at HKD 23.38, down 2.83%, with a trading volume of 6.0081 million shares and a turnover of HKD 140 million [1] - Investment banks predominantly rate Zhaoyan New Drug as a strong buy, with two firms issuing strong buy ratings in the last 90 days, including a recent report from China Merchants Securities [1] Group 2 - Zhaoyan New Drug has a market capitalization of HKD 2.863 billion, ranking 14th in the medical services sector [1] - Key performance indicators for Zhaoyan New Drug compared to the industry average are as follows: ROE at 3.74% (industry average 0.02%), revenue at RMB 1.838 billion (industry average RMB 3.832 billion), net profit margin at 9.11% (industry average -843.36%), gross margin at 15.7% (industry average 39.76%), and debt ratio at 14.44% (industry average 74.15%) [1]

Core Viewpoint - Zhaoyan New Drug (06127.HK) announced an investment in two Industrial and Commercial Bank of China wealth management products totaling RMB 40 million, bringing the total investment in such products to RMB 410 million as of the announcement date [1] Group 1 - The company has subscribed to two wealth management products from the Industrial and Commercial Bank of China [1] - The total investment amount in these wealth management products is RMB 410 million, which includes the newly subscribed amount and the amount that has not yet been redeemed [1]

Group 1 - The company, Zhaoyan New Drug (603127), announced an agreement with Industrial and Commercial Bank of China to subscribe to two wealth management products totaling RMB 40 million [1] - The total investment amount in these wealth management products, including those not yet redeemed as of the announcement date, is RMB 410 million [1]

Group 1 - The company, Zhaoyan New Drug (06127), announced an agreement with Industrial and Commercial Bank of China to subscribe to two wealth management products totaling RMB 40 million [1] - The total investment amount in these wealth management products, including those not yet redeemed as of the announcement date, is RMB 410 million [1]

Core Viewpoint - Zhaoyan New Drug (06127.HK) announced an investment in two Industrial and Commercial Bank of China wealth management products totaling RMB 40 million, bringing the total investment in such products to RMB 410 million as of the announcement date [1] Group 1 - The company has subscribed to two wealth management products from the Industrial and Commercial Bank of China [1] - The total investment amount in these wealth management products is RMB 410 million, which includes the newly subscribed amount and the amount that has not yet been redeemed [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 董 事 會 謹 此 公 佈，於2025年9月19日（交 易 時 間 後），本 集 團 成 員 公 司 昭 衍（蘇 州） 新 藥 剛 與 工 商 銀 行 訂 立 協 議，認 購 兩 項 工 商 銀 行 理 財 產 品 合 共 人 民 幣40,000,000 元，且 連 同 本 公 告 日 期 仍 未 贖 回 的 該 等 工 商 銀 行 理 財 產 品 合 計 投 資 總 額 為 人 民 幣410,000,000元。 （股 份 代 號：6127） 須予披露交易 認購金融產品 認購金融產品 董 事 會 謹 此 公 佈，於2025年9月19日（交 易 時 間 後），本 集 ...